Behandlung auditorischer Halluzinationen bei Schizophrenie mit bilateraler Theta Burst Stimulation - Fortsetzungsantrag

• Antragsteller: Professor Dr. Christian Plewnia
• Fachliche Zuordnung: Klinische Psychiatrie, Psychotherapie und Kinder- und Jugendspychiatrie ; Biologische Psychiatrie
• Förderung: Förderung von 2015 bis 2024
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 276796255

Auditory verbal hallucinations (AH), a cardinal symptom of schizophrenia, are severely distressing and increase the risk for violence and suicide. Their perception is associated with increased activity in speech-related temporoparietal areas of the brain. In up to 25%-30% of patients, AH resist therapeutic efforts. Repetitive transcranial magnetic stimulation (rTMS) can reduce focal brain hyperactivity and, applied to the left temporoparietal cortex, has been shown to ameliorate AH. However, controlled multicentre clinical trials are still missing, effect sizes are moderate, and the treatment is time-consuming. With continuous theta burst stimulation (cTBS), an advanced form of rTMS with brief stimulation sessions is available for a quicker and potentially more effective modulation of cortical hyperactivity and associated AH. With this multicentre, sham-controlled clinical trial, we aim at providing evidence for the efficacy and safety of cTBS in the treatment of AH in patients with schizophrenia. Participating patients (n=64) receive a three weeks course of daily (5/week) cTBS or sham treatment to the left and right temporoparietal cortex (1200 impulses daily). Sham stimulation will be applied by an active sham-coil that allows for a double-blind treatment. Efficacy on AH will be compared between both groups by the PSYRATS-AH subscale at the end of treatment. Secondary endpoints are psychotic symptom severity (PANSS), global functioning (GAF), and clinical global impression (CGI). Follow-up assessments 1, 3 and 6 months after treatment will investigate the stability of treatment effects.

• DFG-Verfahren: Klinische Studien
• Mitverantwortliche: Professor Dr. Andreas Jochen Fallgatter; Professor Dr. Alkomiet Hasan